Not every treatment
starts with yes.

A good candidate for ULTRA laser is generally someone whose treatment goal matches the device's verified applications and whose skin, pigment history, current skin condition, medical history, recent sun exposure, and treatment timing make fractional laser treatment appropriate. Candidacy cannot be determined from age or concern alone. Some patients may be appropriate candidates but need to postpone treatment, while others may benefit more from a different technology.

ULTRA is a 1927 nm non-ablative fractional thulium laser manufactured by Lutronic (Cynosure Lutronic). Its verified applications may include selected pigmentation concerns, sun damage, texture, pore appearance, selected acne marks and scars, and fine surface changes. But having one of those concerns does not automatically make someone a candidate today. Candidacy requires alignment between the concern, the skin, the timing, and the expectation.

Candidacy is not one question. It is two separate questions that must each be answered before a treatment decision is made.

Every treatment decision at JOLA passes through five filters before the device is chosen. The filters are sequential. If any one fails, the treatment does not proceed as planned.

The first filter asks what we are actually treating. ULTRA may belong to conversations involving selected pigmentation, sun damage, texture, pore appearance, selected acne marks and scars, and fine surface changes. These are surface-quality concerns, not structural concerns.

A patient who says "I want better skin" has not yet named a target. The consultation exists to translate that broad desire into a specific, treatable concern before any device is selected. Read the complete ULTRA guide for a full overview of what ULTRA may address.

Some concerns do not belong to a resurfacing conversation. If the primary issue is laxity, dynamic movement, volume loss, facial proportion, vascular redness, advanced scar morphology requiring another approach, or significant surgical laxity, ULTRA may not be the right tool.

A patient can be a poor candidate for ULTRA without being a poor candidate for aesthetic treatment generally. The concern may be real and treatable, but the device may need to be different.

ULTRA should be selected because its verified mechanism fits the target. Not because it is new, popular, trending, strong, or available. Not because someone saw it on social media. Mechanism-to-concern matching is what separates a treatment plan from a product purchase.

The fit filter asks whether a 1927 nm non-ablative fractional thulium laser is the right energy form for the specific concern in front of us. If the answer is uncertain, the consultation should continue before a device is chosen.

Sun damage can include brown spots, roughness, fine lines, and mixed photodamage. Each is a different target. ULTRA may belong to selected sun-damage conversations, but candidacy depends on the specific type of photodamage and the patient's skin. Read more in the ULTRA sun damage guide.

Pigmentation is too broad a word to determine candidacy. Sun spots, freckles, post-inflammatory hyperpigmentation, melasma, and other pigmented lesions are different diagnoses with different treatment considerations. The ULTRA pigmentation guide covers these distinctions in detail.

Texture itself has multiple causes, including roughness, photodamage, pores, scarring, and fine lines. ULTRA may belong to selected texture conversations. The ULTRA texture and pores guide explains when resurfacing may fit a texture concern.

Pores are normal anatomy. The goal of treatment should never be to erase every pore. ULTRA may be considered for improving the appearance of pores in appropriate patients, but candidacy depends on the specific pore concern and the patient's skin.

Acne marks are not one thing. The first question is whether the mark is brown, red, indented, or raised. Each type may belong to a different treatment conversation. The ULTRA acne marks and scars guide covers these classifications.

Acne scar morphology matters. Rolling, boxcar, ice-pick, raised, and mixed scars may require different strategies. ULTRA may be considered for selected scar types, but it should not be assumed that repeated ULTRA treatments alone universally solve every scar. Scar assessment comes before device selection.

A resurfacing technology and a dedicated firmness technology belong to different conversations. If laxity is the primary concern, XERF may belong to the assessment rather than ULTRA. Read the ULTRA + XERF surface and structure guide and the XERF guide for more on how these technologies differ.

Jowling is multifactorial. It can reflect skin laxity, subcutaneous tissue, skeletal structure, and volume distribution. ULTRA is a resurfacing technology, not a structural tightening device. Treating the location without diagnosing the cause is how plans become imprecise.

A line can result from surface quality, movement, laxity, volume change, or combinations of these. Surface lines, movement lines, laxity-related folds, and volume-related folds each belong to a different treatment conversation. ULTRA may be considered for selected surface lines. It should not be expected to address dynamic movement or structural folds.

Treatment choice should account for skin tone, melanin, pigment history, PIH history, melasma, barrier condition, sensitivity, inflammatory conditions, recent tanning, recent sunburn, active acne or infection where relevant, and history of reactions. The skin filter is where many treatment decisions are paused or redirected.

Two people with the same concern can have different candidacy because their skin behaves differently. Skin assessment is not a formality. It is a clinical filter.

Skin tone matters because melanin interacts with laser energy. ULTRA's 1927 nm wavelength and fractional delivery may be considered across a range of skin tones, but candidacy depends on individual assessment, not on a blanket claim about safety for all skin types. Energy parameters, pigment response, PIH risk, provider experience, and the specific diagnosis all influence the decision.

Race does not itself determine candidacy. Skin pigmentation, pigment response, individual history, device characteristics, settings, and diagnosis matter more than racial or ethnic categories. Fitzpatrick type is a tool, not a verdict.

Race does not determine laser candidacy. What matters is the individual's skin pigmentation, pigment response history, the specific concern being treated, device settings, and clinical assessment. Black patients may be appropriate candidates for ULTRA depending on these factors. Individual assessment is always required.

The same standard applies. Asian skin tones vary widely, and PIH history can be a significant factor. Candidacy depends on individual skin assessment, pigment behavior, the specific concern, and device settings, not on a generalized ethnicity-based rule.

Hispanic patients, like all patients, are assessed individually. Skin pigmentation, pigment response, PIH history, melasma history, and the specific concern determine candidacy. Ethnicity alone does not determine whether ULTRA is appropriate.

The Fitzpatrick scale is a classification system that describes how skin responds to UV exposure, ranging from Type 1 (always burns, never tans) to Type 6 (never burns, deeply pigmented). It is used as one factor in laser treatment planning because it helps estimate pigment-related risk.

The scale has limitations. It does not capture every dimension of skin behavior, and it should not be used as the sole determinant of candidacy. A full assessment includes Fitzpatrick type along with pigment history, PIH history, melasma, barrier condition, and the specific concern.

Post-inflammatory hyperpigmentation is pigment darkening that can occur after skin inflammation or injury. A history of PIH can influence laser treatment planning because it suggests the skin may pigment in response to irritation or energy delivery. This does not mean PIH is inevitable, but it means the risk should be discussed and accounted for.

Energy-based procedures can involve pigment-related risks depending on the modality, the patient, the settings, and the response. ULTRA is not exempt from this consideration. A patient with significant PIH history may need a modified approach or may be better suited to a different strategy. Individual assessment and provider experience are essential.

A previous pigment reaction is clinical data. If you have experienced hyperpigmentation after another laser or energy-based treatment, that history should be disclosed during consultation. It may influence how ULTRA is approached, whether settings are modified, whether a test area is considered, or whether another strategy is more appropriate.

Melasma is not ordinary sun damage. It is a complex, recurrent pigmentation condition influenced by UV exposure, visible light, hormonal factors, and genetic predisposition. Melasma requires caution with any energy-based treatment. ULTRA is not a melasma cure, and it should not be positioned as one.

In some cases, laser treatment may be considered as part of a broader melasma management plan. In other cases, laser may not be appropriate. The decision depends on the type of melasma, the patient's history, current triggers, and JOLA's clinical protocol.

Inappropriate treatment of melasma can aggravate pigment. This is why melasma requires individualized assessment rather than a standard laser protocol. If melasma is active or poorly controlled, treatment may be postponed or redirected. The consultation exists to determine whether laser belongs in the plan at all.

A new, changing, irregular, or symptomatic pigmented lesion should receive appropriate medical evaluation before any cosmetic treatment. Not every brown spot is sun damage. Some pigmented lesions require dermatologic assessment rather than a laser appointment. If a spot is new, changing in size or color, irregular in border, or symptomatic, it should be evaluated medically first.

This is not a diagnosis. It is a reminder that cosmetic treatment should not bypass medical assessment when a lesion is clinically concerning.

A patient can be an appropriate future candidate but not appropriate today. Timing is its own filter. Recent sun exposure, active irritation, a compromised barrier, a recent procedure, an upcoming event, or a temporary medication consideration can each move a patient from "yes" to "not yet" without changing the underlying candidacy.

Significant recent sun exposure can affect skin behavior and pigment risk. The consultation includes a discussion of recent sun exposure, outdoor activity, and tanning history. If the skin has been recently exposed, treatment may be postponed until the skin is appropriate for laser.

Tanning changes melanin in the skin, which can affect how the skin responds to laser energy. Active tanning may influence treatment planning and timing. The specific waiting period depends on individual assessment and JOLA protocol. Disclose recent tanning during consultation so the provider can determine whether treatment should be postponed.

Cosmetic self-tanner is different from UV-induced tanning, but product residue and skin preparation may still matter. Follow JOLA's pre-treatment instructions regarding product use and skin preparation. Do not assume that self-tanner is irrelevant simply because it does not involve UV exposure.

Sunburned skin is injured skin. Treating inflamed or injured skin with laser energy is not appropriate. A recent sunburn should be disclosed and may require postponement until the skin has fully recovered. The timeline depends on the severity of the burn and individual healing.

Summer itself is not the diagnosis. What matters is UV exposure, tanning, outdoor schedule, pool and lake time, vacations, sports, and the ability to follow sun precautions. For patients in Dallas, Highland Park, University Park, Preston Hollow, and the Park Cities, year-round UV exposure and outdoor activity can influence treatment planning.

Treatment timing and sun exposure planning matter together. If you are planning significant sun exposure or a beach vacation, discuss the timing with your provider. Treatment too close to significant UV exposure may not be appropriate. The specific interval depends on individual assessment and JOLA protocol.

Recent tanning or sun exposure from travel should be disclosed during consultation. Skin that has been recently exposed may need time to return to its baseline before laser treatment is appropriate.

Being medically appropriate for ULTRA is different from being appropriately timed for an event. Recovery, result development, possible unexpected reactions, series planning, and a buffer before the event all factor into timing. Treatment too close to a wedding may not allow enough time for recovery and result development. Read the ULTRA downtime guide for recovery details.

Irritated skin may need time before laser treatment. If the skin is currently irritated from products, weather, over-exfoliation, or other factors, treatment may be postponed until the skin has calmed. Treating irritated skin can increase the risk of adverse response.

A compromised barrier can appear as significant dryness, burning, irritation, peeling, or over-exfoliation. If the barrier is compromised, skin preparation may begin with less, not more. Restoring barrier health before laser treatment may be the first step. Discuss your current skincare routine and barrier condition during consultation.

Patients should disclose all retinoids, prescription tretinoin, acids, exfoliants, and other active products during consultation. Pre-treatment instructions regarding these products should come from JOLA and should be followed individually. Do not independently stop a prescription medication without appropriate medical guidance.

Retinol use should be disclosed during consultation. Pre-treatment instructions regarding retinol and other topical products should come from JOLA and should be followed individually. Do not independently stop or adjust your skincare routine without guidance from your provider.

Prescription tretinoin should be disclosed during consultation. Pre-treatment instructions regarding tretinoin should come from JOLA and should be followed individually. Do not stop a prescription medication without appropriate medical guidance from your prescribing clinician.

Current or recent isotretinoin use should be disclosed during consultation. Historical laser guidance around isotretinoin has evolved, and the relevant evidence for the specific procedure should be considered. Patients should provide complete medication history, and the decision should follow current evidence and JOLA protocol.

Medication name, dose, indication, photosensitivity, and the specific procedure all matter. Patients should provide a complete medication history during consultation. A simplistic drug list is not a substitute for individualized assessment.

Only medication categories supported by actual treatment protocol should guide pre-treatment planning. Patients should disclose all medications and supplements. Do not stop a prescription medication for a cosmetic procedure without appropriate medical guidance from your treating clinician.

If JOLA postpones elective laser procedures during pregnancy, that is practice policy. Patients should disclose pregnancy during consultation. Do not assume that laser treatment is appropriate during pregnancy without individualized discussion and JOLA protocol.

Breastfeeding should be disclosed during consultation. Current evidence and JOLA policy guide the decision. Do not automatically equate breastfeeding with pregnancy when discussing treatment timing.

Not all acne is identical. Inflammatory lesions, active infection, open areas, post-acne marks, and scars are different situations. Treatment candidacy depends on the current condition and the target. Active inflammatory acne in a treatment area may affect timing, while post-acne marks or scars may be appropriate targets for ULTRA in the right patient.

A history of herpes simplex may matter for certain facial procedures. Disclose cold-sore history during consultation. JOLA protocol guides any pre-treatment considerations. Do not self-prescribe antiviral medication.

Active inflammatory skin disease in the treatment area may affect timing. Eczema should be disclosed during consultation. ULTRA does not treat eczema. If eczema is active in the treatment area, treatment may be postponed until the condition is appropriate.

Active psoriasis in the treatment area may affect timing. Psoriasis should be disclosed during consultation. ULTRA does not treat psoriasis. Individual assessment determines whether treatment should proceed or be postponed.

Rosacea is not simply red skin. If redness or vascular vessels are the primary concern, another modality may be more relevant than a fractional laser. Active inflammation may also affect timing. ULTRA does not treat rosacea. Discuss rosacea history during consultation.

Active infection in a treatment area generally warrants clinical assessment and potential postponement according to protocol. Disclose any active infection during consultation.

Previous laser, IPL or BBL, microneedling, RF microneedling, chemical peels, facials, injectables, XERF, CO2, surgery, and other energy devices should all be disclosed. Recent procedures can affect treatment timing and skin readiness. The specific waiting period depends on the procedure, the individual, and JOLA protocol.

Fraxel is a fractional laser brand family. The exact platform and treatment date matter when assessing readiness for ULTRA. Disclose previous Fraxel treatment during consultation. Read the ULTRA vs Fraxel comparison for more.

RF microneedling history matters when planning ULTRA. Disclose previous Morpheus8 treatment during consultation. Read the ULTRA vs Morpheus8 comparison for more.

Previous microneedling should be disclosed. The specific waiting period depends on individual assessment and JOLA protocol. Read the ULTRA vs microneedling comparison for more.

Recent light-based treatment should be disclosed. Previous IPL or BBL can affect skin readiness for ULTRA. Read the ULTRA vs IPL and BBL comparison for more.

Previous ablative resurfacing matters when planning ULTRA. Disclose previous CO2 treatment during consultation. Read the ULTRA vs CO2 comparison for more.

Previous XERF treatment should be disclosed. Sequencing of ULTRA and XERF follows JOLA protocol. Read the ULTRA + XERF surface and structure guide for more on how these technologies differ and may be combined.

Good candidacy includes an achievable endpoint. The expectation filter asks whether the treatment can reasonably produce the kind of change the patient wants. If the expectation exceeds what the device can deliver, the plan needs reframing before treatment begins.

Some expectations require reframing. ULTRA is not designed to eliminate every pore, erase every scar, lift the face, permanently remove every brown spot, or stop aging with one treatment. These goals are not failures of the patient. They are mismatches between expectation and device.

A consultation should address these expectations directly and without patronizing language. If the goal cannot be met by ULTRA, the conversation should shift to what ULTRA can realistically do, what it cannot, and what other options may exist.

Treatment count follows the target, the response, and the endpoint. Some concerns may be approached with a single treatment. Others may lead to a series. The number is not predetermined. Read the ULTRA treatment count and results guide for more on how treatment series are planned.

This is not a failure. It may mean the patient has multiple layers of concern, multiple targets, or a concern that falls outside ULTRA's primary mechanism. In that case, the plan may include additional modalities, or ULTRA may not be the right starting point at all.

If the primary concern is firmness, laxity, jawline softness, jowling, or neck laxity, XERF may belong to the assessment rather than ULTRA. Read the XERF guide for more on structural skin tightening.

If the concern is dynamic movement, such as forehead lines, frown lines, or crow's feet that appear with expression, a neuromodulator may be more relevant than a resurfacing laser. Read about neuromodulators at JOLA for more.

If the concern is projection, proportion, shape, or volume distribution, facial balancing may be more relevant than resurfacing. Read about facial balancing at JOLA for more.

If the concern involves structural volume loss or biostimulation, Sculptra may be more relevant than a resurfacing laser. Read about Sculptra at JOLA for more.

If the concern is primarily color-focused, such as selected brown or red concerns, another light-based technology may be more appropriate depending on diagnosis. Read the ULTRA vs IPL and BBL comparison for more.

For a more intensive resurfacing discussion, CO2 laser may be relevant where appropriate. Read the ULTRA vs CO2 comparison for more.

A concerning pigmented lesion, an undiagnosed rash, active disease, or a persistent unexplained skin change should receive medical evaluation before cosmetic treatment. Sometimes the right aesthetic decision is to get a medical answer first.

Every consultation at JOLA can end in one of three outcomes. These are conceptual examples, not a self-assessment tool. Actual candidacy must be individually assessed.

Before ULTRA, discuss these questions with your provider.

The consultation follows a sequence designed to test whether ULTRA makes sense before confirming it.

Chey Cope is the Laser Specialist at JOLA Dallas. Her role includes laser candidacy assessment, skin assessment, pigment history evaluation, treatment timing, laser selection, recovery planning, and recognizing when another modality may be better or when treatment should be postponed.

Laser judgment is not only knowing how to treat. It is knowing who to treat, when to treat, and when to wait. A consultation with Chey is designed to determine whether ULTRA fits the concern, the skin, and the timing, not simply to confirm a treatment appointment.

Yes. A consultation does not obligate treatment. Possible outcomes include ULTRA, another treatment, skincare first, waiting, medical evaluation first, or no treatment needed.

Treatment investment depends on the treatment area, the number of treatments needed, the treatment plan, and whether other modalities are appropriate. Consultation and treatment pricing should be discussed directly with JOLA. Contact the practice for current pricing and to schedule a consultation.

WHAT DOES YOUR SKIN NEED FIRST?

FAQ

ULTRA Laser Candidacy and Safety: Frequently Asked Questions